Insights That

Move You Forward

Helping you make smarter decisions, avoid costly missteps, and
bring safe, effective products to market with confidence

What Sponsors Should Expect During the First 90 Days of Working with a CRO

What Sponsors Should Expect During the First 90 Days of Working with a CRO

The first 90 days with a CRO can set the trajectory for your entire clinical trial. Learn what sponsors should expect during study startup, from kickoff and protocol development to site selection, data management, monitoring preparation, and enrollment readiness.

Read More
Clinical Trial Delays Start Long Before Study Subject Enrollment

Clinical Trial Delays Start Long Before Study Subject Enrollment

Clinical trial delays often begin long before the first study subject is enrolled. Learn how protocol development, trial design, regulatory planning, vendor management, database validation, endpoint selection, reimbursement strategy, and other startup activities influence study timelines—and how integrated planning can help keep your clinical program on track.

Read More
Large vs. Boutique CRO: Which Is Right For Your Clinical Trial?

Large vs. Boutique CRO: Which Is Right For Your Clinical Trial?

Choosing between a large CRO and a boutique CRO can significantly impact clinical trial timelines, budgets, and outcomes. This article explores the strengths and limitations of each model, outlines key questions sponsors should ask during vendor selection, and explains why many medical device and combination product companies benefit from a more specialized, hands-on CRO partnership.

Read More
CRO vs. Consulting Firm: What’s the Difference and Why It Matters

CRO vs. Consulting Firm: What’s the Difference and Why It Matters

Success in clinical development depends on knowing when to engage a CRO and when to rely on a consulting firm. CROs excel at executing trials with precision, while consulting firms guide strategy, submissions, and compliance. Understanding the difference—and when you need both—can mean the difference between costly delays and streamlined market approval.

Read More